Hemostasis in humans and other animals is a complex process that controls blood loss after a vascular injury. Factor XIII (FXIII) stabilizes clots primarily by cross-linking fi brin, thus protecting a newly formed clot from fi brinolysis by plasmin. Congenital defi ciencies in humans involving FXIII are associated with delayed bleeding and wound healing and severe spontaneous hemorrhaging. These symptoms can be alleviated by intravenous administration of enriched FXIII plasma fractions. Circulating plasma FXIII is found as a heterotetramer that dissociates in the presence of calcium and thrombin into an active dimer and 2 inactive monomers. The recombinant FXIII under investigation is the active dimer alone. A 3-compartment, nonlinear population pharmacokinetic model was implemented in NON-MEM V and then used to analyze data from preclinical studies in cynomolgus monkeys. The model simultaneously describes endogenous production of dimer (0.622 m g kg − 1 hr − 1 ) and monomer (12.1 m g kg − 1 hr − 1 ), and the administration of recombinant dimer. The model incorporates the rate and extent of complexation of recombinant dimer with available endogenous monomer (6.59 mg − 1 kg hr − 1 ) to form the heterotetramer. Half-lives for dimer, heterotetramer, and monomer (3.33 hours, 2.83 days, and 3.94 hours for A 2 , A 2 B 2 , and B, respectively) were estimated, along with their variability in the population studied.
INTRODUCTION
Platelet-derived FXIII appears only in a dimer form, composed of 2 A subunits (protein-glutamine g-glutamyltransferase, E.C. 2.3.2.13). 1 Plasma-circulating FXIII is a heterotetramer, composed of 2 A subunits and 2 B subunits. The enzymatic activity of FXIII resides in the A subunit. The B subunit acts as a carrier in plasma, extending the half-life of the heterotetramer (A 2 B 2 ) compared with that of the dimer (A 2 ) or monomer (B) alone. 2 In the presence of activated thrombin and calcium ions, the plasma FXIII heterotetramer dissociates into 2 B subunits and the A 2 dimer. A 2 , then activated, acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine cross-links between fi brin molecules, stabilizing the fi brin clot. In addition, A 2 has been shown to cross-link alpha-2-plasmin inhibitor, fi bronectin, to the fi brin alpha chains. 3 Muszbek et al provided a recent overview of many of the details of this important protein. 4 Lack of FXIII is a rare congenital defi ciency disease in humans. 5 Prolonged bleeding, delayed wound healing, severe spontaneous hemorrhage, and habitual abortion characterize the disease. Defi ciency is categorized into 2 classes: type I defi ciency, which is the lack of both the A and B subunits, and type II, which is the lack of the A subunit alone. Bone marrow is thought to be the primary site of A subunit synthesis, 6 while the B subunit is synthesized in the liver. 7 Current treatment strategies involve intravenous injection of concentrated plasma-derived A 2 B 2 on a prophylactic basis. Recently, a recombinant form of FXIII A 2 dimer (rA 2 ) has been under investigation as an alternative therapy for FXIII defi cient individuals.
OBJECTIVES
The objective of this work was to model the complex pharmacokinetics of intravenously administered rA 2 in cynomolgus monkeys. As the endogenous dimer (cA 2 ) was indistinguishable from the recombinant protein, it was necessary to account for this confounding factor. The formation of the heterotetramer complex was observed to be very fast (minutes) when compared with the half-life of the heterotetramer (days), and so some compromises in the complexity of the model were expected owing to sampling constraints. Finally, the model was required to be robust enough to support the use of multiple, complex immunological assays.
MATERIALS AND METHODS
The test article, recombinant human Factor XIII (rA 2 ; ZymoGenetics Inc, Seattle, WA) was supplied as 5.0 mL frozen isotonic solutions in 3% sucrose, 20 mM histidine, 200 mM E694 glycine, 0.01% (wt/vol) polysorbate 20, pH 8.0, with a nominal concentration of active ingredient (rFXIII) of 5 mg/mL.
Study Design
Data from 2 preclinical studies were analyzed in this study. Preclinical data was gathered in Macaca fascicularis (cynomolgus) monkeys ( n = 4 at each dose level), which were dosed intravenously once with 0.5, 1.0, or 5.0 mg/kg rA 2 (ZymoGenetics). Plasma samples were drawn at 0.25, 1, 2, 4, 8, 24, 72, 120, 168, 240, 336, 504, and 672 hours after dosing. Multiple-dose response studies were also performed in cynomolgus monkeys ( n = 6 at each dose level), where 0.3, 3.0, and 6.0 mg/kg of rA 2 However, this would increase the complexity of the model, and require intensive sampling early in the study to estimate this fast process. We do not expect dissociation of unactivated FXIII to play a role, and so this process is discounted. The binding constant, K d , has been estimated to be 4 × 10 − 7 M, and free A 2 in the plasma has not been noted in any study. 9 Graphically, we can depict this system as a 3-compartment model with nonlinear rate constants, as shown in Figure 1 (see Jacquez for a review of compartmental modeling 10 ).
The following differential equations were used to describe the fate of the 3 molecular species:
A 2 B 2 , and B, respectively, from the plasma (hr − 1 ); InfA 2 and InfB describe the constant infl ux of endogenous cA 2 and B, respectively (mg kg − 1 hr − 1 ); D is the bolus dose amount administered intravenously on a per body-weight basis (mg kg − 1 ); d (t) is the Dirac delta function (hr − 1 ). It is important to note that the differential equation system is then expressed in terms of (mass protein)/(body-mass)/(time), since the dose is expressed per unit of body weight in these studies. The coeffi cients of 2 and 3 in the differential equations arise from the stoichiometry of the biochemical association: 1A 2 + 2B → 1A 2 B 2 . The tetramer differential equation contains the counter-intuitive constant " 3, " which arises from summing the contribution of B (2) and A 2 (1). Maintenance of a constant A 2 B 2 level in the plasma requires balancing endogenous production with protein turnover rates. Thus, the initial conditions of the system are completely specifi ed by the kinetic rate constants and endogenous production rates, and can be determined by solving the system of differential equations at steady-state (t = 0): where A 2 (t), A 2 B 2 (t), and B(t) are the masses of A 2 , A 2 B 2 , and B, respectively, in the plasma as a function of time (mg kg − 1 ); Ka is the rate constant describing the association of A 2 and B (mg − 1 kg hr − 1 ); keA 2 , keA 2 B 2 , and keB are the fi rst-order rate constants that describe the elimination of A 2 ,
Although each of the ELISA assays measure from the same plasma space, the capture and detection species have different affi nities for their targets. Due to the fact that the total A 2 assay measures in A 2 -equivalents and the A 2 B 2 assay in A 2 B 2 -equivalents, there should be a 2:1 ratio of the estimates for volume of distribution of total A 2 vs A 2 B 2 . However, an observed underestimate of existing A 2 B 2 using the total A 2 assay contributes to a more pronounced difference in volume of distribution estimates than can be explained by our expected 2:1 ratio. This results in the need to use different scale factors (volumes of distribution). The resulting measurement equations are:
where VtA 2 , VA 2 B 2 , and VB represent the volumes of distribution that account for antibody affi nity differences for the total A 2 , A 2 B 2 , and free B assays, respectively (L kg − 1 ); each assay is assumed to have a measurement error that is proportional to the model for the measurement (total A 2 and A 2 B 2 assay) or simply constant (free B assay). The free B assay was modeled in this manner due to the data set including very low values for this assay (zero in some cases).
Under a proportional error model, these data would be thought of as very precise, and so they would be weighted heavily during the model-fi tting process, resulting in skewed under-prediction of the baseline levels.
Population/Statistical Model
Population pharmacokinetics is the study of sources of variability in PK profi les in individuals comprising a population targeted for drug treatment. Physiological, pathological, genetic, allometric, and many other differences between subjects can vary the dose-concentration profi les between subjects. Population pharmacokinetics attempts to ascribe measurable differences between subjects, with the ultimate goal of tailoring a dose by those factors. 11 Several approaches have been suggested, but we focus on mixed-effects modeling as a framework to account for many sources of variability. 12 Many of the parameters described so far are, by construction, weight normalized. The dosage levels per animal were also weight normalized. This simplifi ed the development of a population statistical model, as a source of betweensubject variability, body mass, was already accounted for. However, the elimination rate-constants were not weightnormalized, and it was necessary to add a random-effect to each of these parameters. Our subject-specifi c model parameters can then be mapped to parameters that do not change over the population (fi xed-effects, u ) and parameters that change subject-to-subject (random effects, h ):
Finally, we must specify the distributional assumptions for the random variables we have introduced ( h and e ). We assume independent, normal distributions for these random variables, and so each individual's random-effects can be modeled as:
where model parameters Ka, InfB, InfA 2 , VtA 2 , VA 2 B 2 , and VB are modeled as fi xed-effects that do not vary across the population; the individual's model parameters keA 2 , keA 2 B 2 , and keB are modeled as random effects whose values are infl uenced by their typical values across the population but can still vary subject-to-subject.
where N(.) is the normal distribution; W is a diagonal, 3 × 3 matrix that describes the variance of the between-subject random-effects; S is a diagonal, 3 × 3 matrix that describes the variance of the within-subject (measurement error) random-effects.
Our population fi xed-effects parameter vector that we wish to estimate is a combination of the fi xed effects that appear in the individual's parameters ( q ), the variance of the between-subject random-effects ( W ), and the variance of the within-subject random-effects ( S ), yielding 15 parameters of interest:
The model was implemented in NONMEM V, using the ADVAN8 subroutine (arbitrary stiff differential model) with a tolerance of 1E-8. The PDx-Pop interface was used to access NONMEM functionality and produce plots and reports (GloboMax, Hanover, MD) The fi rst-order approximation to the maximum likelihood was selected as the objective function, with the requirement of 3 signifi cant digits in the solution. The differential equation solver was challenged by this stiff system of equations, and numerical issues precluded the use of more rigorous objective functions.
RESULTS
Estimates for the population fi xed effects were computed in less than 1 hour on a desktop personal computer (Intel Pentium 4, 2.3 GHz). The " typical " subject (where the random effects are set to zero) predictions well accounted for the actual data for both the single-and multiple-dose studies at all dose levels. Moreover, if the random effect values for each subject were also included, the agreement (as expected) improved. Figure 2 shows the 1674 data points (y-axis) collected from all studies plotted against the typical prediction (top panel). A perfect agreement would generate x-y pairs on a unity line. Points far from the unity line indicated possible disagreement between the model prediction and data (goodness of fi t). We can see some 20 points that fell far from the unity line, all in cases where the prediction was higher than the actual data. However, this subset represented ~1% of the total data. When we also compared the " individualized " fi ts to the actual data (where the effects specifi c for each subject were included), the overall goodness
of fi t was improved ( Figure 2 , lower panel). There remained a group of data points where the model over predicted, but the number was fewer. The problem can be traced to the washout observation period of the tetramer in the multipledose trial. The elimination rate of the tetramer appeared to be faster than in the single-dose trials, suggesting that the elimination kinetics may be more complicated than the assumed fi rst-order profi le. However, the tetramer levels that accumulated during the multiple-dose trials were much higher than normal physiological levels (and therefore outside of projected clinical relevance), so it appeared sufficient for our purposes to retain the kinetic structure that described typical physiological conditions.
Reviewing goodness of fi t in this way is useful in capturing the overall quality of the predictions by distilling the volume of data into a concise set of plots. We now expand the volume of these goodness-of-fi t metrics to partition the data by assay (total A 2 , A 2 B 2 , and free B) and dose level. The doses were split into low, medium, and high (0.5, 1.0, and 5.0 mg/kg for the single-dose and 0.3, 3.0, and 6.0 mg/kg for the multiple-dose trial) doses, giving us a sense of how the model fi t behaved over a 10-or 20-fold range of doses. In Figures 3 , 4 , and 5 (total A 2 , A 2 B 2 , and free B, respectively), the dose levels index the columns. The fi rst row of these fi gures shows the data value (DV) against the " typical " population predictions (PRED, plusses) and individualized predictions (IPRED, circles). The second row of these fi gures shows the weighted residuals (WRES) of the single-(plusses) and multiple-dose (circles) data and fi ts vs time.
The third row of these fi gures shows the DV and PRED vs time for the single-dose study, while the fourth row displays the same information for the multiple-dose study. Typical population predictions were connected by lines as a guide for the eye, not by simulated model values, so care should be taken when interpolating between measured time points. Beginning with the total A2 assay ( Figure 3 ) population and individual fi ts (top row), we can see that the model generally agreed with the data, except at very low and very high measurements (DV). The weighted residuals ( Figure 3 , second row), which were separated into single-dose (plusses) and multiple-dose (circle) groups indicated that the model systematically under-predicted the multiple-dose measurements and over-predicted the single-dose measurements. The third and fourth (single-and multiple-dose, respectively) rows in Figure 3 show the typical fi t (solid line) and measurements (plusses) vs time, which confi rmed this disagreement. However, the model had no provision for differences between the 2 studies. Possible rationales will be explored in the Discussion section. Figure 4 shows the same information for the A 2 B 2 assay. Here however, the typical and individualized fi ts (top row) appeared in very good agreement. The residuals indicated a slight under prediction for the single-dose study and a slight over prediction for the multiple-dose study (second row from the top). This was a reversal of the pattern seen for the total A 2 assay. Again, the overall fi ts can be seen for the single-and multiple-dose studies ( Figure 4 , third and fourth row). The model could not reconcile the apparent rapid elimination of the heterotetramer in the multiple-dose study ( Figure 4 , fourth row, third column) and the much slower elimination in the case of the single-dose study ( Figure 4 , third row, third column). Again, the model had no provision for differences between studies. Here, however, there was the possibility that the elimination of the heterotetramer was not monoexponential. Finally, Figure 5 shows the same information for the free B assay. The weighted residuals showed some discrepancy in the multiple-dose fi t, and the baseline free B levels were underpredicted in the multiple-dose studies. In general, however, the fi ts were in good agreement with the experimental data. Once we were reasonably confi dent in the goodness of fi t for the model, we turned our attention to the parameter estimates gained from the data. Table 1 lists the fi xed effects, or parameters that do not change over the population, estimated from the data. The meanings of the parameters are complex, and so we divide the results into 3 sections, following the division detailed in the Methods section.
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A typical subject in the population studied would assume PK parameters ( ) equal to those in the first section of Table 1 . The estimates were well defined, having a easily to half-lives of 3.33 hours, 2.83 days, and 3.94 hours for A 2 , A 2 B 2 , and B, respectively. The volumes of distribution were 142 mL, 32.7 mL, and 209 mL for VtA 2 , VA 2 B 2 , and VB, respectively, and can be compared with blood volume in a normal cynomolgus monkeys (~3.5 kg = 270 mL).
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The second section of Table 1 lists the between-subject variability for parameters ( ⍀ ) that we have modeled as changing from subject to subject. The elimination rates, which were not normalized by weight, were modeled as varying subject-to-subject, and the variances were found to be 0.0629, 0.0268, and 0.151 for keA 2 , keA 2 B 2 , and keB, respectively. The uncertainty of these parameter estimates was higher than for the typical parameter values, still being, at worst, a %RSE of 137%. Parameters relating to the fate of the recombinant dimer (keA 2 , Ka) indicated that these reactions were very fast, and diffi cult to estimate given the sampling schedules used in these studies. We can also express the degree of infl uence subject-subject variability may have on these parameters: how much might any one individual in the population deviate from the " typical " population value?
The square root of these variances × 100% yields the between-subject variability (BSV) of the PK parameters, which were reported in Table 1 as 25.1%, 16.4%, and 38.9% for keA 2 , keA 2 B 2 , and keB, respectively.
The fi nal section of Table 1 reports the estimated variability ( ⌺ ) of the assays. In the case of the total A 2 and A 2 B 2 assays, the measurement error was modeled as being proportional to the model value. The (unit-less) variances of the measurement error for these assays were found to be 0.0730 and 0.0751, respectively. The free B assay measurement error was modeled as being constant across the range of the assay, and the variance of the error was found to be 0.0857 mg 2 L − 2 . These estimates can again be expressed relative to the assay values, yielding residual, unexplained variation (RUV) in the assays of 27.0%, 27.4%, and 0.293 mg L − 1 .
DISCUSSION
Complex, noisy assays in biomedical experiments are common, but remain problematic. First, the noise level, if not properly modeled, can degrade parameter estimate quality. Second, the complexity can prevent unambiguous identification of a parameter of interest. Here, the total A 2 assay, sensitive to A 2 B 2 and A 2 , confounds the estimation of 2 elimination rate constants (keA 2 and keA 2 B 2 ). Third, the sampling schedule may not be suitable for estimating all the parameters of interest. assay errors were modeled as being proportional to the model prediction, and so the proportionality constant was estimated and reported here as a unit-less variance. The residual, unexplained error in the measurements (RUV) = (estimate mean of the variance) 1/2 × 100% is reported in the last column. In contrast, the free B assay error was best modeled as being additive and independent of the model prediction, and so the estimate of this variance is expressed here as the square of the measurement units. The residual, unexplained error in this measurement RUV = (estimate mean of the variance) 1/2 is also reported, now in the units of the measurement.
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The model included no provisions for differences between studies. There are 2 possible sources of differences that we have considered, but could not suffi ciently justify for inclusion in our model. First, there is the possibility that the 2 populations of cynomolgus monkeys are truly different. The animals were all of Chinese origin, and both studies were performed at the same laboratory. Gender distribution was approximately equal between studies. Second, there is the possibility that some of the processes controlling this system are more nonlinear than we propose here. The formation of the heterotetramer and possible attenuation of the production rates will be examined later, and for the moment we will focus on the possibility that the elimination of the species (here, modeled as monoexponential decay) is infl uenced by the dose and regimen. The A 2 B 2 elimination shows the largest deviation by exposure ( Figure 4 , third column, third and fourth rows). The single-dose prediction falls below the data, indicating that the elimination rate is too fast (third row), while the multiple-dose prediction falls above the data after the fi nal dose (fourth row), indicating that the elimination rate is too slow. The total concentration for the heterotetramer in the multiple-dose trial is 4-fold higher than in the single-dose trial, so we can speculate that the assumption of a constant elimination rate constant may not hold across this range of exposures.
The endogenous production of A 2 and B were described as simply as was plausible as constant infusions into the plasma. The relative production rates indicate that the production of the B monomer is being maintained at a rate 20-fold greater than the production of A monomer. This agrees well with the observations that uncomplexed A 2 dimer is not observed in plasma in primates and man, and that there is an equal amount of uncomplexed and complexed B in plasma in man. 2 No attenuation mechanism was modeled, although we explored the possibility that A 2 and B production were regulated by the concentrations of each of the species, as has been suggested previously. 13 In these cases, identifi ability issues appeared, as the elimination rates could be adjusted with the attenuation to yield any number of possible solutions. Radiolabeled exogenous species could be introduced in new studies to determine the elimination rates independently.
Nonlinearities in the dynamics of the system are introduced in the simplest possible manner by making the fl ux of A 2 and B to A 2 B 2 dependent on the counterpart species. Thus, an overwhelming amount of A 2 with nearly no B present, as is the case with higher doses after all the available free B is complexed, will result in very little further production of tetramer. The multiple-dose A 2 B 2 assay data also shows a lack of superposition, which can be explained by noting that the free B level does not recover to the same amount just before the next dose. With less free B available to form a complex, less A 2 is complexed. Uncomplexed A 2 has a relatively shorter-half life, meaning excess dimer is quickly Where it was appropriate, population modeling was applied to include between-subject variability within the model. Weight is an important covariate, and many parameters within the model were normalized by weight due to the dosing strategy. The elimination rate constants were not weight normalized, and so here we included random-effects. Estimates from these studies show that between-subject variability is present and is appreciable compared with the central tendency of the parameters. One measure of impact, BSV, shows that one standard deviation of the between-subject variability can be equal to 16% to 40% of the parameter value. Moreover, the estimate for the elimination rate of the dimer is very imprecise (%RSE = 137%). We did initially attempt to fi x the association rate constant (Ka) to a very fast value, but this is a somewhat unsatisfactory assumption.
Finally, we believe this model may be useful as a prospective tool for simulating other dosing regimens. Figure 6 shows single-and multiple-dose experiments simulated using the typical population parameter values. We can ignore the assay variability and begin to get a sense of how the species are interacting. This is key, as the interaction is nonlinear in nature. Moreover, the complex immunological assays obscure the actual amounts of each of the individual species. The model can be used to simulate the expected actual amount of the species present in the blood both before and after exogenous administration.
CONCLUSIONS
The nonlinear mixed-effects model we have described was conceptualized from the basic stoichiometry of the prodrug formation: 1A 2 + 2B → 1A 2 B 2 . The initial data that was collected showed that the recombinant protein had an important interaction with the endogenous protein present in the blood. Therefore, we sought a model that could perform the following:
• seamlessly include endogenous production of native proteins as well as exogenous administration of exogenous recombinant proteins
• incorporate complex, noisy immunological assays that did not discriminate between endogenous and exogenous A 2 dimer
• capture very fast (seconds: heterotetramer complexation) and very slow (days: heterotetramer elimination) dynamic processes
• explain the nonlinear dose -response relationship be tween rA 2 administration and rA 2 B 2 formation
• simulate other dosing regimens
The model developed describes the PK profi le of recombinant FXIII dimer when administered to cynomolgus monkeys. Between-study differences, although not understood, were reasonably minor and did not require modifi cations to the model. At the high dose levels, the data began showing signs of deviating from the model predictions, indicating that some of the assumptions underlying the model were not valid across such a wide exposure range. However, looking forward to the use of the model in the future, we expect that the range of clinical exposure (as is usually the case) will not be as dramatic as seen in this animal model. 14 Figure 6 . " Typical " /population predictions for a single bolus of 5 mg/kg rA 2 (top panel) and multiple boluses of 6 mg/kg rA 2 (bottom panel) administered daily for 14 days. The time axis (x-axis) is extended to include 100 hours of predose baseline levels detected by the assays. The A 2 B 2 assay is shown as a solid line, while the total A 2 assay is shown as a broken line. The free B assay levels are so low as to not show well on these scales, but a solid line can be seen near 1.0 on the y-axis that drops to near zero, while uncomplexed rA 2 is present just after dosing.
